This paper is in the following e-collection/theme issue:

Formative Evaluation of Digital Health Interventions (2422) Registered Report (561) Mobile Health (mhealth) (2945) mHealth for Wellness, Behavior Change and Prevention (2875)

Published on in Vol 6, No 10 (2022): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/41415, first published .
Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study

Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study

Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study

Authors of this article:

Sherif M Badawy1, 2 Author Orcid Image ;   Lisa DiMartino3 Author Orcid Image ;   Donald Brambilla3 Author Orcid Image ;   Lisa Klesges4 Author Orcid Image ;   Ana Baumann4 Author Orcid Image ;   Ebony Burns5 Author Orcid Image ;   Terri DeMartino5 Author Orcid Image ;   Sara Jacobs3 Author Orcid Image ;   Hamda Khan6 Author Orcid Image ;   Chinonyelum Nwosu6 Author Orcid Image ;   Nirmish Shah5 Author Orcid Image ;   Jane S Hankins6, 7 Author Orcid Image ;   Sickle Cell Disease Implementation Consortium8
Article Authors Cited by (5) Tweetations (8) Metrics

Journals

  1. Hankins J, Potter M, Fernandez M, Melvin C, DiMartino L, Jacobs S, Bosworth H, King A, Simon J, Glassberg J, Kutlar A, Gordeuk V, Shah N, Baumann A, Klesges L. Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease. Frontiers in Health Services 2023;2 View
  2. Rai P, Okhomina V, Kang G, Martinez H, Hankins J, Joshi V. Longitudinal effect of disease‐modifying therapy on left ventricular diastolic function in children with sickle cell anemia. American Journal of Hematology 2023;98(6):838 View
  3. Hankins J, Brambilla D, Potter M, Kutlar A, Gibson R, King A, Baumann A, Melvin C, Gordeuk V, Hsu L, Nwosu C, Porter J, Alberts N, Badawy S, Simon J, Glassberg J, Lottenberg R, DiMartino L, Jacobs S, Fernandez M, Bosworth H, Klesges L, Shah N. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Blood Advances 2023;7(23):7190 View
  4. Nwosu C, Khan H, Masese R, Nocek J, Gollan S, Varughese T, Bourne S, Clesca C, Jacobs S, Baumann A, Klesges L, Shah N, Hankins J, Smeltzer M. Recruitment Strategies in the Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization Study (meSH): Multicenter Survey Study. JMIR Formative Research 2024;8:e48767 View
  5. Green N, Manwani D, Aygun B, Appiah‐Kubi A, Smith‐Whitley K, Castillo Y, Soriano L, Jia H, Smaldone A. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease. Pediatric Blood & Cancer 2024;71(4) View